Grafalon versus Thymoglobulin after kidney transplant in people at risk of slow recovery
Compares Grafalon with Thymoglobulin in people aged 65 or older receiving a kidney transplant.
Key facts
- Who runs it
- Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana
- Where
- Valencia, SpainSee the site
- Trial code
- Registry title
- Efficacy and safety of Grafalon® versus Thymoglobulin® for induction therapy in kidney transplant recipients at high risk of delayed graft function: a phase IV randomized open-label study
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 104 people, planned
- Started
- 11 Nov 2026
- Expected to end
- 1 Nov 2027
- Type of study
- Interventional
- Record updated
- 19 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people older than 65 who are receiving a kidney transplant with a high risk that the new kidney starts working late. It compares two drugs, Grafalon® and Thymoglobulin®.
- Age
- Older than 65 years
- Sex
- All sexes
- Disease stage
- Receiving a kidney graft at high risk of delayed graft function. Examples: older donor, long cold ischemia time (over 19 hours), retransplant, controlled asystole donor.
- Earlier treatment
- No earlier stem cell transplant or solid organ transplant other than kidney. No perfusion machine used between explant and implant.
- Biomarker or test result
- No donor-specific anti-HLA antibodies in the recipient.
Main reasons for not taking part
- Donor-specific anti-HLA antibodies in the recipient
- Earlier stem cell transplant or solid organ transplant other than kidney
- Active clinically significant bacterial, viral or fungal infection
- Known allergy to Thymoglobulin®, Grafalon®, tacrolimus, mycophenolate, everolimus or prednisone
- Pregnancy or plan to become pregnant during the study
This trial only enrols participants who have had an organ transplant. The registry sentence this rests on: Patients receiving a kidney graft at high risk of delayed graft function, defined as: - expanded criteria donors (>60 years, or >50 years plus one of: hypertension, diabetes mellitus, Creatinine > or equal 1.5 mg/dL, death by stroke) - Prolonged ICU stay (4-5 days, hemodynamic instability) - cold ischemia time > 19 hours, acute renal failure in donor - pediatric en bloc donors - Retransplants - Low immunological risk recipients without HLA incompatibility - Controlled asystole donors
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Older than 65 years
- Signed informed consent
- Patients receiving a kidney graft at high risk of delayed graft function, defined as: - expanded criteria donors (>60 years, or >50 years plus one of: hypertension, diabetes mellitus, Creatinine > or equal 1.5 mg/dL, death by stroke) - Prolonged ICU stay (4-5 days, hemodynamic instability) - cold ischemia time > 19 hours, acute renal failure in donor - pediatric en bloc donors - Retransplants - Low immunological risk recipients without HLA incompatibility - Controlled asystole donors
Who cannot take part
- Recipient with donor-specific anti-HLA antibodies
- Use of perfusion machine between explant and implant
- Prior hematopoietic stem cell or solid organ transplant (except kidney)
- Any other medical or social condition that renders the patient unsuitable for participation or completion of the full study period
- Patients at risk of recurrent atypical hemolytic uremic syndrome requiring C5 inhibitor prophylaxis
- Active clinically significant bacterial, viral, or fungal infection
- Known hypersensitivity to tacrolimus, mycophenolate mofetil/mycophenolic acid, mTOR inhibitors (everolimus), or prednisone
- Known hypersensitivity to Thymoglobulin® or Grafalon® or any of their excipients
- Laboratory abnormalities: WBC <3000×10⁹/L, Neutrophils <1000×10⁹/L, Platelets <100×10⁹/L
- Pregnancy or intention to become pregnant during the study
Where in Spain
- Hospital Universitario Dr. Peset AleixandreValencia, SpainTaking people
About the trial
What the trial wants to find out
To compare the time-course evolution of lymphocytes in patients receiving Grafalon® versus Thymoglobulin® during the first year post–kidney transplant
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Phase IV, randomized, open-label study comparing the use of Grafalon® versus Thymoglobulin® in non-sensitized patients who have received a kidney transplant at high risk of delayed graft function
- Plain-language title
- Grafalon versus Thymoglobulin after kidney transplant in people at risk of slow recoveryGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 19 October 2026